Entrada Therapeutics (TRDA) Liabilities and Shareholders Equity (2020 - 2026)

Entrada Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $335.5 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 31.03% year-over-year to $335.5 million; the TTM figure through Mar 2026 stood at $1.6 billion (down 26.74% YoY), while the FY2025 annual figure was $377.4 million, down 28.3% from the prior year.
• Liabilities and Shareholders Equity was $335.5 million for Q1 2026 at Entrada Therapeutics, down from $377.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $582.0 million in Q2 2024 to a low of $252.1 million in Q4 2022.
• Historically, Liabilities and Shareholders Equity has averaged $429.3 million across 5 years, with a median of $469.2 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity surged 107.31% in 2022, then plunged 31.03% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $252.1 million in 2022, then surged by 86.15% to $469.2 million in 2023, then advanced by 12.18% to $526.3 million in 2024, then fell by 28.3% to $377.4 million in 2025, then slipped by 11.09% to $335.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $335.5 million (Q1 2026), $377.4 million (Q4 2025), and $412.9 million (Q3 2025), per Business Quant data.